子宫浆液性癌单纯前哨淋巴结定位与系统淋巴结清扫的生存比较
回顾性分析1996至2017年245例子宫浆液性癌手术患者,79例接受单纯前哨淋巴结定位,166例接受系统淋巴结清扫;两组在I/II期和III期疾病中的2年总生存率均无显著差异;作者所在机构已用前哨淋巴结算法替代系统淋巴结清扫作为主要分期方式。
要点
- 245例子宫浆液性癌患者中,79例(32.2%)接受单纯前哨淋巴结定位,166例(67.7%)接受系统淋巴结清扫。
- I/II期患者2年总生存率:前哨淋巴结组96.6%(SE±3.4) vs 系统淋巴结清扫组89.6%(SE±2.2),p=0.8。
- III期患者2年总生存率:前哨淋巴结组73.6%(SE±10.2) vs 系统淋巴结清扫组77.3%(SE±5.8),p=0.8。
核心结论
- 单纯前哨淋巴结定位与系统淋巴结清扫在I-III期子宫浆液性癌中产生相似的生存结局。
研究设计与样本
- 回顾性研究,纳入1996年1月1日至2017年12月31日在本机构接受初次手术的新诊断子宫浆液性癌患者245例,分为单纯前哨淋巴结定位组(79例)和系统淋巴结清扫组(166例)。
主要发现
- 系统淋巴结清扫组中132例(79.5%)行腹主动脉旁淋巴结清扫,前哨淋巴结组无一例行腹主动脉旁淋巴结清扫。
- 前哨淋巴结组和系统淋巴结清扫组的中位年龄分别为66岁和68岁(p>0.05)。
- 前哨淋巴结组和系统淋巴结清扫组的I/II期疾病比例分别为67.1%(n=53)和64.5%(n=107)(p>0.05)。
- 前哨淋巴结组和系统淋巴结清扫组的中位随访时间分别为23个月(范围1-96)和66个月(范围4-265)(p<0.001)。
- I/II期疾病(n=160,60.1%)的2年总生存率:前哨淋巴结组96.6%(SE±3.4) vs 系统淋巴结清扫组89.6%(SE±2.2),p=0.8;III期疾病(n=77)的2年总生存率:前哨淋巴结组73.6%(SE±10.2) vs 系统淋巴结清扫组77.3%(SE±5.8),p=0.8。
临床怎么用
- 本研究中心的做法是,前哨淋巴结算法已替代系统淋巴结清扫作为该情况下的主要分期方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of our study was to assess survival among patients with uterine serous carcinoma (USC) undergoing sentinel lymph node (SLN) mapping alone versus patients undergoing systematic lymphadenectomy (LND). METHODS: We retrospectively reviewed patients undergoing primary surgical treatment for newly diagnosed USC at our institution from 1/1/1996-12/31/2017. Patients were assigned to either SLN mapping alone (SLN cohort) or systematic LND without SLN mapping (LND cohort). Progression-free (PFS) and overall survival (OS) were estimated using Kaplan-Meier method, compared using Logrank test. RESULTS: 245 patients were available for analysis: 79 (32.2%) underwent SLN, 166 (67.7%) LND. 132 (79.5%) in the LND cohort had paraaortic LND (PALND) versus none in the SLN cohort. Median age: 66 and 68 years in the SLN and LND cohorts, respectively (p>0.05). Proportion of stage I/II disease: 67.1% (n = 53) and 64.5% (n = 107) in the SLN and LND cohorts, respectively (p>0.05). Median follow-up: 23 (range, 1-96) and 66 months (range, 4-265) in the SLN and LND cohorts, respectively (p < 0.001). Two-year OS in stage I/II disease (n = 160, 60.1%): 96.6% (SE ± 3.4) and 89.6% (SE ± 2.2) in the SLN and LND cohorts, respectively (p = 0.8). Two-year OS in stage III disease (n = 77): 73.6% (SE ± 10.2) and 77.3% (SE ± 5.8) in the SLN and LND cohorts, respectively (p = 0.8). CONCLUSIONS: SLN mapping alone and systematic LND yielded similar survival outcomes in stage I-III USC. In our practice, the SLN algorithm has replaced systematic LND as the primary staging modality in this setting.
引用
- Basaran D, Bruce S, Aviki EM, et al. Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. Gynecol Oncol. 2019. PMID: 31739992. doi:10.1016/j.ygyno.2019.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。